343 related articles for article (PubMed ID: 25874530)
1. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Bonaccorso S; Sodhi M; Li J; Bobo WV; Chen Y; Tumuklu M; Theleritis C; Jayathilake K; Meltzer HY
Bipolar Disord; 2015 Aug; 17(5):528-35. PubMed ID: 25874530
[TBL] [Abstract][Full Text] [Related]
2. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
[TBL] [Abstract][Full Text] [Related]
3. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Nikolac Perkovic M; Nedic Erjavec G; Zivkovic M; Sagud M; Uzun S; Mihaljevic-Peles A; Kozumplik O; Muck-Seler D; Pivac N
Psychopharmacology (Berl); 2014 Sep; 231(18):3757-64. PubMed ID: 24595507
[TBL] [Abstract][Full Text] [Related]
4. BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis.
Huang E; Hettige NC; Zai G; Tomasi J; Huang J; Zai CC; Pivac N; Nikolac Perkovic M; Tiwari AK; Kennedy JL
Pharmacogenomics J; 2019 Jun; 19(3):269-276. PubMed ID: 30181602
[TBL] [Abstract][Full Text] [Related]
5. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.
Tsai A; Liou YJ; Hong CJ; Wu CL; Tsai SJ; Bai YM
Neuromolecular Med; 2011 Dec; 13(4):328-33. PubMed ID: 21956459
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
7. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
8. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.
Meltzer HY; Bonaccorso S; Bobo WV; Chen Y; Jayathilake K
J Clin Psychiatry; 2011 Dec; 72(12):1602-10. PubMed ID: 21813074
[TBL] [Abstract][Full Text] [Related]
9. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
10. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
[TBL] [Abstract][Full Text] [Related]
11. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
13. Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients.
Ventriglio A; Gentile A; Baldessarini RJ; Martone S; Vitrani G; La Marca A; Bellomo A
Eur Psychiatry; 2014 Sep; 29(7):402-7. PubMed ID: 24439513
[TBL] [Abstract][Full Text] [Related]
14. The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study.
Liu J; Wang P; Sun L; Guan X; Xiu M; Zhang X
Transl Psychiatry; 2021 Sep; 11(1):458. PubMed ID: 34482368
[TBL] [Abstract][Full Text] [Related]
15. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
16. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
17. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
[TBL] [Abstract][Full Text] [Related]
18. Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.
Fjukstad KK; Engum A; Lydersen S; Dieset I; Steen NE; Andreassen OA; Spigset O
Eur Psychiatry; 2018 Feb; 48():71-78. PubMed ID: 29331603
[TBL] [Abstract][Full Text] [Related]
19. The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.
Burghardt KJ; Pop-Busui R; Bly MJ; Grove TB; Taylor SF; Ellingrod VL
Clin Transl Sci; 2012 Dec; 5(6):486-90. PubMed ID: 23253673
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
